Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
For the detection and quantification of endogenous levels of natural and/or recombinant Human Osteoprotegerin proteins.
LS-F24642 is a 96-well enzyme-linked immunosorbent assay (ELISA) for the Quantitative detection of Human OPG / Osteoprotegerin in samples of Cell Culture Supernatants, Plasma, Serum and Urine. It is based upon a Sandwich assay principle and can be used to detect levels of OPG / Osteoprotegerin as low as 5 picograms per milliliter.
All LSBio Custom kits have been predesigned and all necessary components, including antibodies and standards have been identified. Upon receiving a custom kit order, the kit will be assembled and quality control tested before being shipped out. Kit assembly and testing typically takes 4 to 6 weeks. In most cases the final kit is based on the Sandwich assay principle, with a few being Competitive EIA based. Specifications such as Range, Sensitivity, and Precision are defined upon completion. In the event that the custom kit cannot be successfully developed with 6 weeks of the order date, the customer will be notified and the order canceled at no cost.
Cell Culture Supernatants, Plasma, Serum, Urine
96-Well Strip Plate
Colorimetric - 450nm
93.7 - 6000 pg/ml
Due to their limited shelf life, LSBio ELISA kits are not typically stocked as finished goods. Upon receipt of an order each kit is assembled and tested to ensure that it meets specifications before shipping. Minor changes may occur to the Range, Sensitivity, and Precision. In the event of a significant change the order would be confirmed with the customer before shipping. ELISA kit lot numbers reflect the date of final assembly and testing for each specific kit rather than a bulk manufactured lot. All kits are tested to confirm that they fall within their defined Inter- and Intra- assay coefficient of variation.
Coated 96-well Strip Plate
Biotinylated Detection Antibody (100x)
Avidin-Biotin-HRP Complex (100x)
Biotinylated Detection Antibody Diluent
Avidin-Biotin-HRP Complex Diluent
Wash Buffer (20x)
Adhesive Plate Sealers
Osteoprotegerin (OPG) is identical to osteoclastogenesis inhibitory factor (OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis. OPG is considered to play an important role in the regulation of bone resorption by modifying osteoclast differentiation.2 Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. It can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity. OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential. OPG also plays a role in the vascular system.
Store at 4°C for 6 months or at -20°C for one year. Avoid freeze/thaw cycles.
Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.